Local News

• Abbott completes acquisition of Ibis Biosciences, a subsidiary of Isis  Isis Pharmaceuticals and Abbott announced that Abbott has completed its purchase of Ibis Biosciences, an Isis subsidiary, for a closing purchase price of $175 million.
  Isis Pharmaceuticals, Inc. January 06, 2009  
• MedImmune submits Marketing Authorisation Application in EU for intranasal flu vaccine  MedImmune, the global biologics unit of AstraZeneca, announced that it has submitted a Marketing Authorisation Application (MAA) for its nasal spray live attenuated influenza vaccine (LAIV), which is now being reviewed by the European Medicines Agency (EMEA).
  AstraZeneca January 06, 2009  
• Endo Pharmaceuticals to acquire Indevus Pharmaceuticals  Endo Pharmaceuticals and Indevus Pharmaceuticals announced that they have entered into a merger agreement under which Endo will commence a tender offer to acquire 100 percent of the outstanding shares of Indevus for approximately $370 million, or $4.50 per Indevus share, in cash.
  Endo Pharmaceuticals January 05, 2009  
• Dick Bond leaving Tyson Foods  Dick Bond, president and chief executive officer of Tyson Foods, announced he is leaving the company, effective immediately. Leland Tollett, former chairman and CEO of the company, has agreed to return to the company as President and CEO on an interim basis.
  Tyson Foods, Inc. January 05, 2009  
• Escalon buys Immunodiagnostic Systems division  Escalon Medical acquired the hematology business of Immunodiagnostic Systems Holdings for $5.9 million. Hematology, the branch of biology that looks at blood and blood-forming organs, is one of the fields for which Escalon supplies equipment to laboratories.
  Phildelphia Business Journal January 05, 2009  
• PPD enters into strategic collaboration with Merck  PPD announced it has entered into a strategic collaboration with Merck & Co. involving vaccine testing and assay development. Under the agreements, PPD purchased Merck's 130,000 square-foot vaccine testing laboratory and related equipment in Wayne, Penn.
  PPD, Inc. January 05, 2009  
• Alexion Pharmaceuticals and PDL BioPharma resolve patent dispute  PDL BioPharma and Alexion Pharmaceuticals jointly announced that the companies have entered into a definitive license agreement and settlement agreement that resolve the legal disputes between them relating to Alexion's humanized antibody, Soliris(R) (eculizumab) and PDL's patents.
  Alexion Pharmaceuticals, Inc. January 05, 2009  
• FDA Cardio Renal Advisory Committee to review Daiichi Sankyo, Lilly drug prasugrel  Daiichi Sankyo Company and Eli Lilly and Company confirmed that the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) will review prasugrel during an advisory committee hearing on February 3, 2009.
  Eli Lilly and Company December 31, 2008  
• Johnson & Johnson completes acquisition of Omrix Biopharmaceuticals  Johnson & Johnson announced the completion of its previously announced acquisition of Omrix Biopharmaceuticals, a fully-integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products.
  Johnson & Johnson December 30, 2008  
• Pegloticase BLA filing accepted for priority review by FDA  Savient Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company's Biologics License Application (BLA) for pegloticase, a novel biological drug for treatment-failure gout (TFG) patients.
  Savient Pharmaceuticals, Inc. December 29, 2008  

   (next 10 articles)